Bluejay Completes SYMON-II Enrollment, Cash Runway Extended to Q2 2027
BJDX sits 27% above its 52-week low of $0.83 on light trading volume (0.1× avg).
Summary
Bluejay Diagnostics reported Q2 2026 results with $9.6M in cash, up from $5.2M at year-end, extending its runway to Q2 2027. The company completed targeted enrollment of 750 patients in its SYMON-II pivotal study for the Symphony IL-6 sepsis test, a key step toward an FDA 510(k) submission. This follows the June private placement that raised $8.5M gross and the activist investor exit in early June. The strengthened balance sheet and enrollment milestone reduce near-term financing risk, though the company still needs $10-14M more and faces going concern and Nasdaq delisting risks. Watch for analytical and clinical validation data from SYMON-II, which will determine the timing of the regulatory submission.
At the time of this announcement, BJDX was trading at $1.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.83 to $16.68. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.